Therapeutic Application of Fibrinogen in Spine Surgery: A Review Article

Bardia Barimani, Philippe Moisan, Carlos Santaguida and Michael Weber

*Int J Spine Surg* 2021, 15 (3) 549-561
doi: [https://doi.org/10.14444/8075](https://doi.org/10.14444/8075)
http://ijssurgery.com/content/15/3/549

This information is current as of September 15, 2023.

**Email Alerts**  Receive free email-alerts when new articles cite this article. Sign up at: [http://ijssurgery.com/alerts](http://ijssurgery.com/alerts)
Therapeutic Application of Fibrinogen in Spine Surgery: A Review Article

BARDIA BARIMANI, MBBS,1 PHILIPPE MOISAN, MD, CM,1 CARLOS SANTAGUIDA, MD,2 MICHAEL WEBER, MD, PHD3,4
1Division of Orthopedic Surgery, 2Department of Neurology and Neurosurgery, 3Department of Surgery, McGill University, Montreal, Quebec, Canada, 4Montreal General Hospital, Montreal, Quebec, Canada

ABSTRACT

Background: The aim of this review is to investigate current uses of fibrinogen as a tool to reduce operative and postoperative blood loss in different surgical fields especially orthopedic spine surgery. This is a systematic review.

Methods: MEDLINE (via Ovid 1946 to June 1, 2020) and Embase (via Ovid 1947 to June 1, 2020) were searched using the keywords “fibrinogen”, “surgery”, and “spine” for relevant studies. The search strategy used text words and relevant indexing to identify articles discussing the use of fibrinogen to control surgical blood loss.

Results: The original literature search yielded 407 articles from which 68 duplications were removed. Three hundred thirty-nine abstracts and titles were screened. Results were separated by surgical specialties.

Conclusions: Multiple studies have looked at the role of fibrinogen for acute bleeding in the operative setting. The current evidence regarding the use of fibrinogen concentrate in spine surgery is promising but limited, even though this is a field with the potential for severe hemorrhage. Further trials are required to understand the utility of fibrinogen concentrate as a first-line therapy in spine surgery and to understand the importance of target fibrinogen levels and subsequent dosing and administration to allow recommendations to be made in this field.

Complications

Keywords: fibrinogen, spine surgery, hemorrhage, hemostasis

INTRODUCTION

Fibrinogen is an essential protein in the management of bleeding. When hemostatic activation occurs, during the coagulation cascade, thrombin cleaves fibrinogen and hastens fibrin polymerization, which forms a strong network important in clot formation.1 Acute blood loss and volume resuscitation can lead to dilutional coagulopathy and a reduction in fibrinogen levels. In recent literature, fibrinogen is highlighted as a key substrate for managing bleeding in surgical patients.2–6 In this review article, we will study the application of fibrinogen in a variety of surgical settings, with a focus on orthopedic spine surgery.

During major surgery extensive blood loss is frequent. Clot formation is essential in reaching and maintaining hemostasis. Fibrinogen has been found to be the first clotting factor to fall below critical levels during major hemorrhage.7 It is thus evident that fibrinogen levels are invaluable in the hemostasis process and that a deficiency can lead to serious complications during major surgery.

Fibrinogen is a 340 kDa plasma glycoprotein8 with a half-life of 2.7–3.6 days, which is synthesized in the liver.9 It is a substrate of the following enzymes: plasmin, thrombin, and factor XIIIa. During the coagulation cascade, thrombin cleaves the fibrinogen molecule, which gives the soluble fibrin monomer.1 During the initial stage of the clot formation, these monomers create a network that traps red blood cells. This clot is then strengthened by factor XIIIa and the elasticity of the clot and resistance to fibrinolysis is increased.10 Platelet aggregation is also aided by fibrinogen as it acts as a ligand for glycoprotein IIb/IIIa receptors positioned on platelets.11

Fibrinogen levels can fall to critical levels due to numerous variables. Commonly in major hemorrhage and when fibrinogen metabolism exceeds synthesis leading to a reduction in concentration.12 Another way by which hypofibrinogenemia occurs is with hemodilution during volume replacement.13,14 Additionally, colloids can impair polymerization of fibrin.15 This will lead to poor clot quality and will subsequently worsen the hemor-
rhage. This highlights the reason for optimizing fibrinogen levels preoperatively, perioperatively, and postoperatively.

Normal Fibrinogen Levels

Normal fibrinogen levels are between 150 and 350 mg/dL,\textsuperscript{16} and studies have shown that hypofibrinogenemia increases the risk of perioperative bleeding in different types of surgery. Previous literature suggests 100 mg/dL as the threshold for administering fibrinogen in patients with congenital fibrinogen deficiency.\textsuperscript{17}

Management strategies for fibrinogen deficiency due to major hemorrhage and dilution effects are still primitive. Studies have shown that a serum fibrinogen level above 200 mg/dL is required for fibrinogen to function optimally.\textsuperscript{18} It has been found that fibrinogen can in fact increase with age and varies within different age groups.\textsuperscript{19} This suggests that fibrinogen supplementation must be personalized.

Fibrinogen Preparation and Administration

Fibrinogen is produced from human plasma and converted to lyophilized powder. During this preparation process, the product is pasteurized and viruses inactivated.\textsuperscript{3} This procedure also removes antibodies and antigens making it a safe product by preventing potential immunological and allergic reactions. The safety of fibrinogen administration is increased by the fact that it does not require blood type screening before use and can be stored at room temperature allowing fast use.\textsuperscript{3,6}

Administration of cryoprecipitate is the most common way to supplement a patient with fibrinogen. This method is used in North America and in the United Kingdom, with other countries using lyophilized fibrinogen concentrates instead.\textsuperscript{6} Dosing of fibrinogen can be personalized depending on the severity of the bleeding and plasma fibrinogen concentration preoperatively. However, in an acute setting, it has been recommended to use 1–2 g with the opportunity to administer more if needed.\textsuperscript{5,20} Larger doses, up to 8 g are also safe to administer in severe cases.\textsuperscript{15} The dose can be calculated as follows:

Fibrinogen concentrate dose (g) = desired increase in plasma fibrinogen level (g L) \( \times \) plasma volume (L)

Fibrinogen concentration can be measured very swiftly using thromboelastometry (ROTEM device, TEM International, Munich, Germany) or thrombelastography.\textsuperscript{21} This allows physicians to assess the patient fibrinogen levels during a procedure and thus enable immediate intervention with fibrinogen supplementation if required. The device used to measure the fibrinogen level (ROTEM device) can even establish the concentration of fibrinogen is needed.\textsuperscript{6}

METHODS

A systematic review of the literature was conducted in line with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Figure 1). The search was performed in both MEDLINE (via Ovid 1946 to June 1, 2020) and Embase (via Ovid 1947 to June 1, 2020). Search terms included subject headings specific to the relevant databases. The search strategy included the use of the keywords: “fibrinogen”, “surgery”, “spine”, and “bleeding”. The initial search yielded 407 articles published any time before June 2020; after removal of duplicates, 338 articles were screened by 2 reviewers, BB and PM. After review, 26 were assigned a level of evidence according to Oxford Centre for Evidence-Based Medicine 2009 Guidelines and included in the final article (Table 1). Inclusion criteria included application of fibrinogen in surgery and data collected included the study methodology, dose of fibrinogen administered, timing of administration, and qualitative effect on bleeding. If other publications were noted during the screening of reference lists, they were also added. Due to the heterogeneity of the data and variability in the experimental study methods, it was not possible to conduct a statistical analysis. For this reason, a comprehensive review of the clinical application of fibrinogen in surgery is presented.

RESULTS

The systematic review conducted resulted in 407 articles. After the removal of duplicates, 339 articles were screened based on their title and abstract. Subsequently, 26 articles were found to be relevant based on the inclusion criteria (Figure 1). Following this, the manuscripts were divided into the following surgical categories: pediatrics (n = 1), obstetrics (n = 2), cardiac (n = 14), trauma (n = 3), orthopedics (n = 2), spine (n = 2), and urology (n = 2).
Pediatric Surgery

Blood loss in major pediatric surgery is associated with high risk for morbidity and mortality. These surgeries frequently require transfusion of allogeneic blood products. There is robust evidence that side effects related to blood transfusions are associated with increased morbidity and mortality especially in children. The European Society of Anesthesiology guidelines recommend fibrinogen concentrate as the management of perioperative bleeding in acquired hypofibrinogenemia. Fibrinogen concentrates represent a possible technique for increasing hemostatic competence and reducing reliance on allogeneic blood products.

A study performed on pediatric major craniosynostosis surgery showed that transfusion requirements could be reduced significantly by using fibrinogen concentrate. There is also a case report of a 7-year-old child who sustained major abdominal and pelvic injuries in which fibrinogen concentrate had a major role in achieving successful management. Additionally, a comparative randomized study of 63 pediatric patients underwent cardiac surgery treated with fibrinogen concentrate or cryoprecipitate in which fibrinogen concentrate was shown to be a valuable option for controlling bleeding and avoiding transfusion in pediatric cardiac surgery patients. An observational study of children with severe acquired hypofibrinogenemia during chemotherapy for acute lymphoblastic leukemia supplemented by fibrinogen concentrate at an adequate dosage and in selected cases suggested reduction of the risk of transmission of viral infection and better outcome.

Obstetrics

Postpartum hemorrhage is a major cause of maternal morbidity and mortality worldwide. Physical causes such as uterine atony and placental complications if associated with hemostatic impairment can lead to consumptive and dilutional coagulopathies. This can result in life-threatening bleeding requiring rapid volume resuscitation and allogeneic blood transfusion.

A case series of postpartum hemorrhage showed an additive effect of fibrinogen concentrate associ-
Table 1. Overview of clinical studies detailing fibrinogen concentrate administration.

| Study                | Design                           | Quality of Evidence | Number of Patients Receiving Fibrinogen Concentrate | Fibrinogen Dose                                                                                                      | Bleeding                                                                                                                      | Conclusions                                                                                                                   |
|----------------------|----------------------------------|---------------------|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Pediatrics           | Haas et al 2015<sup>22</sup>      | Prospective study   | 49                                               | 30 mg/kg intraoperative with FIBTEM MCF trigger level of <13 mm (early substitution)                                  | Calculated blood loss as percent of estimated total blood volume decreased from a median of 160% (IQR, 110%–190%) to a median of 90% (IQR, 78%–110%) (P = .017). | Intraoperative fibrinogen concentrate administration decreases bleeding and transfusion requirements in the setting of craniosynostosis surgery, but not scoliosis. |
| Obstetrics           | Wikkelsø et al 2015<sup>23</sup>  | Randomized controlled trial | 249                                              | Pre-emptive, single dose of 2 g of fibrinogen                                                                   | No evidence for the use of 2 g fibrinogen concentrate as pre-emptive treatment for severe PPH (early postpartum hemorrhage) in patients with normofibrinogemina. | Fibrinogen concentrate normalized laboratory coagulation measurements and improved hemorrhage. |
| Bell et al 2010<sup>24</sup> | Case series                     | 4                   | 6                                                | Median dose of 3 g administered during acute hemorrhage                                                         | Fibrinogen concentrate normalized laboratory coagulation measurements and improved hemorrhage. |                                                                                                                                  |
| Cardiovascular surgery | Shams et al 2019<sup>25</sup>    | Observational study | 2c                                               | Perioperative median dose of 2 g of fibrinogen                                                                | The median bleeding volume was 150 (25th–75th percentile 70–240) mL/h before, and 60 (40–110) mL/h after transfusion of fibrinogen and/or platelet concentrate (P < .001). | Fibrinogen infusion resulted in an increase in fibrinogen concentration and clot stability (P = .001), but had no effect on platelet aggregation. |
| lup et al 2018<sup>26</sup> | Retrospective matched study      | 2b                  | 73                                               | Intraoperative median dose of 1 g of fibrinogen                                                              | Higher bleeding in the first 12 and 24 h postoperatively (P < .001) and required significantly more transfusion of blood products (P < .001) when compared with the control group. | Administration of 1 g of fibrinogen based on low-FIBTEM values and clinical bleeding after protamine administration does not stop bleeding and the need for transfusion of allogeneic blood products. |
| Erdoes et al 2019<sup>27</sup> | Guideline                       | 1a                  |                                                   |                                                                                                                   |                                                                                                                               | Administration of fibrinogen concentrate for maintaining physiological fibrinogen activity in the case of microvascular postcardiopulmonary bypass bleeding appears to be indicated. The available evidence does not suggest aiming for supranormal levels. Fibrinogen does not seem to increase adverse effects. |
| Study | Design | Quality of Evidence | Number of Patients Receiving Fibrinogen Concentrate | Fibrinogen Dose | Bleeding | Conclusions |
|-------|--------|---------------------|-----------------------------------------------|----------------|------|-------------|
| Li et al 2018<sup>28</sup> Anesthesia and Analgesia | Meta-analysis | la | 597 | Between 1 and 8 g preoperative and intraoperative | Fibrinogen significantly reduced incidence of allogeneic red blood cell transfusion (risk ratio, 0.64; 95% CI, 0.49–0.83; I = 0%; P = .001). No significant differences were found for other clinical outcomes. The transfusion of fibrinogen in patients undergoing HT may be associated with reductions in postoperative bleeding, the number of packed red blood cells, and hospital length of stay; however, it may enhance postoperative acute kidney injury. |
| Jahangirifard et al 2018<sup>29</sup> Clinical and Applied Thrombosis/Hemostasis | Retrospective study | 2b | 23 | 2 g preoperative | | |
| Bilecen et al 2017<sup>30</sup> JAMA | Randomized, placebo-controlled, double-blind clinical trial | 1b | 60 | Single intravenous dose to achieve 2.5 g/L | | |
| Kikura et al 2017<sup>31</sup> Masui: The Japanese Journal of Anesthesiology | Retrospective cohort study | 2b | 92 | 2–3 g intraoperative fibrinogen | | |
| Ranucci et al 2015<sup>32</sup> Journal of the American Heart Association | Randomized double-blinded, placebo-controlled trial | 1b | 58 | Dose (g) = Target FIBTEM – actual FIBTEM × (body weight (kg)/140) | Postoperative bleeding was significantly (P = .042) less in the treatment arm (median, 300 mL; IQR, 200–400 mL) than in the control arm (median, 355 mL; IQR, 250–600 mL). | Fibrinogen concentrate limits postoperative bleeding after complex heart surgery, leading to a significant reduction in allogeneic blood product transfusions. No safety issues were raised. |
| Yamamoto et al 2014<sup>33</sup> Journal of Cardiothoracic Surgery | Retrospective study | 2b | 25 | Titrated to achieve levels of more than 200 mg/dL | In cases of fibrinogen concentrate given, the average volume of intraoperative blood loss decreased by 64% (5640 mL in the FFP group versus 2140 mL in the group of fibrinogen concentrate). | In patients showing severe hypofibrinogenemia during TAA surgery, timely administration of fibrinogen concentrate just after removal from CPB is effective for hemostasis, and therefore in reducing blood loss and transfused volumes. |
| Study                        | Design                               | Quality of Evidence | Number of Patients Receiving Fibrinogen Concentrate | Fibrinogen Dose | Bleeding                                                                 | Conclusions                                                                 |
|------------------------------|--------------------------------------|---------------------|---------------------------------------------------|----------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Rahe-Meyer et al 2013        | Placebo-controlled randomized trial   | 1b                  | 61                                                | Dose (g) = (target FIBTEM MCF – actual FIBTEM MCF) (mm) × (body weight [kg] / 70) × 0.5 g/mm with target FIBTEM MCF = 22 mm Study medication was administered if clinically relevant bleeding occurred | Hemostatic therapy with fibrinogen concentrate in patients undergoing aortic surgery significantly reduced the transfusion of allogeneic blood products. |
| Bilecen et al 2013           | Cohort analysis using prospectively collected data | 2b                  | 264                                               | Intraoperative median dose of 2 g | Fibrinogen concentrate infusion during surgery did not reduce postoperative blood loss and transfusion, and no increased risk for clinical adverse events was measured. |
| Sadeghi et al 2014           | Placebo-controlled randomized trial   | 1b                  | 30                                                | 1 g dose of fibrinogen 30 min preoperative | Less postoperative bleeding was observed in the fibrinogen group (477 ± 143 versus 703 ± 179, P = .0001). |
| Rahe-Meyer et al 2009        | Prospective study                    | 2b                  | 6                                                 | Intraoperative The dose of fibrinogen concentrate equaled (22 FIBTEM MCF) × body weight = 140 | FIBTEM-guided postcardiopulmonary bypass administration of fibrinogen concentrate resulted in improved intraoperative management of coagulopathic bleeding in thoracoabdominal aortic aneurysm operations and reduced transfusion and 24-hour drainage volume. |
| Karlsson et al 2009          | Prospective randomised pilot study    | 2b                  | 20                                                | Preoperative, single dose of 2 g of fibrinogen | Fibrinogen concentrate infusion reduced postoperative blood loss by 32%. |
| Trauma                       | Observational study                  | 2b                  | 223                                               | Median total dose of fibrinogen; 12 g (4 g concentrate + 8 g in FFP) administered perioperatively 2–4 g administered in context of acute traumatic injury | In bleeding patients, higher plasma fibrinogen might be associated with higher rates of survival. |
| Weiss et al 2011             | Posthoc analysis of data from a prospective study | 2b                  | 144                                               | 7 g median dose of concentrated fibrinogen | Decreased allogenic transfusion in patients with major blunt trauma. |
| Inmerhofer et al 2013        | Retrospective study                  | 2b                  | 128                                               | Fibrinogen concentrate is an effective and rapid first-line hemostatic therapy for severe trauma-induced bleeding. |
| Study | Design | Quality of Evidence | Number of Patients Receiving Fibrinogen Concentrate | Fibrinogen Dose | Bleeding | Conclusions |
|-------|--------|---------------------|-----------------------------------------------|----------------|----------|-------------|
| Orthopedics Najafi et al 2014<sup>39</sup> *Acta Medica Iranica* | Randomized controlled trial | 1b | 30 | 30 mg/kg fibrinogen after induction of general anaesthesia | Mean transfused blood products in the fibrinogen and control group was 0.8 ± 1.01 units and 1.06 ± 1.2 units, respectively ($P = .53$). | The prophylactic administration of fibrinogen concentrate was safe and effective in reducing bleeding in the perioperative period of total hip arthroplasty. |
| | | | | | | |
| Haas et al 2008<sup>40</sup> *Anesthesia and Analgesia* | Retrospective | 2b | 9 | Mean 680 mg (76 mg/kg) | | Administration of fibrinogen concentrate effectively improves fibrinogen polymerization and total clot strength, which were the main underlying problems of dilutional coagulopathy in children undergoing craniosynostosis surgery. |
| Spine surgery Pournajafian et al 2015<sup>41</sup> *Journal of Isfahan Medical School* | Prospective study | 2b | 41 | 1 g in 100 cc of normal saline infused within 5 min after induction | Mean blood loss: 533.3 ± 157.9 versus 679.0 ± 130.0 mL, $P = .003$. | Prophylactic infusion of fibrinogen in candidates for posterior spinal fusion surgery may significantly decrease the amount of intraoperative hemorrhage and the need for blood transfusion. |
| | | | | | | |
| Javaherforoosh et al 2019<sup>42</sup> *Anesthesia Pain Medicine* | Double-blind randomized controlled trial | 1b | 15 | 1 g of fibrinogen in 50 cc of sterile water | Intraoperative hemorrhage in the intervention group was significantly lower than the control group (225.33 ± 180.431 versus 530.00 ± 275.032, $P < .001$). In addition, postoperative bleeding in the intervention group was significantly lower than the control group (43.33 ± 41.690 versus 107.33 ± 85.228, $P < .001$). | Hemorrhage during and after the operation in the control group was significantly higher than that of the intervention group ($P < .05$). |
### Table 1. Continued.

| Study                          | Design                              | Quality of Evidence | Number of Patients Receiving Fibrinogen Concentrate | Fibrinogen Dose | Bleeding                                      | Conclusions                                                                 |
|-------------------------------|-------------------------------------|---------------------|------------------------------------------------------|-----------------|------------------------------------------------|-----------------------------------------------------------------------------|
| Carling et al 2016<sup>43</sup>  
*Thrombosis Research*         | Prospective observational study     | 2<sup>b</sup>        | 52                                                   |                 | Spinal fusion surgery patients with a low preoperative fibrinogen concentration (≤2.5 g/L) had a greater total perioperative median bleeding volume than patients with fibrinogen > 2.5 g/L (2430 [400-6560] mL versus 1390 (400-7420) mL, *P* = .029). | Measurement of preoperative fibrinogen plasma concentration can identify spinal fusion patients with an increased risk of excessive perioperative bleeding. |
| Urology                      |                                      |                     |                                                      |                 |                                               |                                                                            |
| Soleimani et al 2017<sup>44</sup>  
*Journal of Thrombosis and Haemostasis* | Double-blind placebo-controlled and randomized study | 1<sup>b</sup>        | 31                                                   | Single dose of 2 g fibrinogen | Mean blood loss for fibrinogen and placebo (521 versus 557 mL, respectively) and after (291 versus 341 mL, respectively) surgery. | No difference was observed in bleeding between the fibrinogen and placebo groups. |
| Fenger-Eriksen et al 2009<sup>45</sup>  
*Journal of Thrombosis and Haemostasis* | Randomized controlled trial         | 1<sup>b</sup>        | 10                                                   | 45 mg/kg        | Postoperatively, in the placebo group, 8 out of 10 patients (80%) required red blood cell transfusion within 48 h after the end of the operation, whereas only 2 patients out of 10 (20%) in the group treated with the fibrinogen concentrate required additional red blood cell transfusion (*P* < .05). | Fibrinogen concentrate improved clot strength after hemodilution and reduced red blood cell transfusion requirements. |

Abbreviations: CI, confidence interval; CPB, cardiopulmonary bypass; FFP, fresh frozen plasma; HT, heart transplant; IQR, interquartile range; TAA, Thoracic aortic aneurysm repair.
ated with conventional treatments for obstetric hemorrhage associated with hyperfibrinogenemia secondary to dilutional and consumptive coagulopathies.\textsuperscript{24} These findings support that fibrinogen concentrate infusion has a role in controlling obstetric hemorrhage. A randomized clinical trial investigated the use of fibrinogen concentrate in acute postpartum hemorrhage in 249 randomly assigned subjects. They studied the effect of early empirical administration of fibrinogen concentrate on blood transfusion in postpartum hemorrhage and concluded that preemptive administration of fibrinogen concentrate did not reduce red blood cell transfusion in patients with normal fibrinogen levels.\textsuperscript{23} A retrospective analysis comparing fibrinogen concentrate usage in 36 patients with acquired hyperfibrinogenemia to 64 patients who received cryoprecipitate was conducted. This study supported the use of fibrinogen concentrate and showed superiority in comparison with cryoprecipitate in relation safety and overall benefit.\textsuperscript{51} Multiple large randomized double-blind placebo controlled trials are ongoing to provide evidence on the efficacy, safety, and feasibility of fibrinogen concentrate during acute bleeding in postpartum hemorrhage.\textsuperscript{52,53}

**Cardiac Surgery**

Complex cardiovascular surgeries often require blood transfusion perioperatively and postoperatively. Although blood components are considered safe, it may be associated with serious adverse effects.\textsuperscript{54,55} Thus, alternative options to reduce blood transfusion are desirable.

A prospective randomized controlled trial of 61 patients was conducted where elective thoracic or thoracoabdominal aortic replacement surgery involving cardiopulmonary bypass (randomized into 2 groups—managed with fibrinogen concentrate or placebo) showed significant reduction of blood products transfusion in the treatment group.\textsuperscript{34} Another randomized controlled study showed fibrinogen concentrate as targeted first-line hemostatic therapy in aortic surgery significantly provides short-lived increases in plasma fibrinogen and fibrin-based clotting after aortic surgery.\textsuperscript{56} Shams et al\textsuperscript{25} have also demonstrated a similar increase in fibrinogen levels and improved clot stability without having an effect on platelet aggregation. In a prospective pilot study including 20 patients who underwent elective coronary artery bypass graft surgery, prophylactic fibrinogen infusion significantly reduced postoperative blood loss and helped maintain hemoglobin levels.\textsuperscript{6} Other prospective and retrospective studies have also supported the administration of fibrinogen concentrate during cardiovascular surgery and are associated with the reduction in blood transfusion and incidence of postoperative bleeding.\textsuperscript{5,6,28,57} This reduction in bleeding is more significant in patients with underlying hypofibrinogenemia\textsuperscript{33} specifically at a fibrinogen level that is less than 100–130 mg/dL.\textsuperscript{31} Most studies look at intraoperative administration, but as described by Sadeghi et al\textsuperscript{36} preoperative administration seems to have a similar effect. Administration of 1 g of fibrinogen seems to be an insufficient amount. As described by Lupu et al\textsuperscript{26} this dose does not stop bleeding and does not reduce the need for transfusion. Although fibrinogen administration seems safe, Jahangirifard et al\textsuperscript{29} observed an increased risk of postoperative acute kidney injury after its administration.

**Trauma**

Trauma is one of the leading causes of death for individuals up to the age of 45 years worldwide.\textsuperscript{58} Hemorrhage is responsible for up to 40% of deaths related to trauma and is considered the leading preventable cause in this setting.\textsuperscript{59} Massive hemorrhage can result in a coagulopathy leading to hypofibrinogenemia, which can subsequently extend to tissue damage. Initial volume resuscitation with fluid causes dilution of coagulation factors.\textsuperscript{2} In addition, acidosis and hypothermia associated with massive bleeding play a major role in fibrinogenolysis and fibrinogen synthesis inhibition.\textsuperscript{60} As a result, fibrinogen replacement is important in these circumstances to restore baseline hemostasis.\textsuperscript{61,62}

Several clinical reports have shown the potency of using fibrinogen concentrate along with antifibrinolytic medication to correct trauma-related coagulopathy and restore hemostasis without the need for transfusion of either platelets or fresh frozen plasma.\textsuperscript{20,38} Various studies composed of large numbers of traumatic patients described the applicability and use of fibrinogen concentrate and/or prothrombin complex concentrate in correcting coagulopathy. They showed reduction in the requirement of blood and platelet transfusion while improving survival rates in comparison with receiving fresh frozen plasma.\textsuperscript{20,38,63}
A retrospective study enrolled 435 patients divided into 2 groups (treated with fibrinogen concentrate in the first 24 hours of arrival to hospital and control group) showed no significant difference in plasma fibrinogen concentration up to 7 days posttrauma.\(^6^4\) On the other hand, a randomized trial of 50 patients demonstrated that the infusion of fibrinogen concentrate within 1 hour of arrival to hospital in the case of trauma in patients at risk of significant hemorrhage is feasible, fast, and improves plasma fibrinogen levels considerably.\(^6^5\)

A number of randomized controlled trials taking place internationally in multiple centers such as the RETIC trial, STATA trial, FiIrSRT, E-FIT1, and PRooF-iTH are currently investigating the use of factor concentrates in traumatic hemorrhage.\(^6^6\) These trials will certainly help in addressing significant shortage in the evidence regarding the use/role of fibrinogen concentrate in severe trauma.

**Urology**

Radical cystectomy and prostatectomy are urologic procedures with a significant bleeding potential,\(^6^7,6^8\) and administration of fibrinogen in the perioperative setting is a therapeutic option used in many centres based on limited evidence and contradictory results.

Soleimani et al\(^4^4\) did not see a hemostatic advantage from administering 2 g of fibrinogen to patients undergoing prostate surgery. Fenger-Eriksen et al\(^4^5\) noticed improved hemostasis and decreased bleeding when administering a dose of 45 mg per kg during cystectomy.

**Orthopedics**

Orthopedic surgeries are often associated with severe hemorrhage due to impaired coagulation system and poor hemostasis intraoperatively. A randomized controlled trial looking at the prophylactic administration of fibrinogen in the perioperative period of a total hip arthroplasty was conducted by Najafi et al\(^3^9\) where 30 patients were either given fibrinogen concentrate or placebo. The 2 groups had similar preoperative fibrinogen, hemoglobin, and platelet levels. The prophylactic administration of fibrinogen concentration was found to be safe and effective in lowering the bleeding perioperatively during total hip arthroplasty surgery.\(^3^9\) A prospective study looking at 66 major orthopedic surgery patients who randomly received volume resuscitation with modified gelatin solution, hydroxyethyl starch, or Ringer lactate showed that fibrinogen concentration supplementation can reverse the effects of intravascular volume therapy and promote hemostasis.\(^4\)

**Spine Surgery**

Spine surgery is associated with high rates of hemorrhage intraoperatively and postoperatively.\(^2^1\) This leads to depletion of coagulation factors. Treatment with high volumes of fluid replacement can give rise to dilutional coagulopathy and weakened fibrin formation. A prospective study looking at the prophylactic administration of fibrinogen in posterior spinal fusion surgery was assessed by Pournajafian et al\(^4^1\) where 41 patients were randomly assigned to the intervention of 1-g fibrinogen infusion preoperatively versus placebo. They found the need for blood transfusion was significantly higher in the control group suggesting that the prophylactic infusion of fibrinogen in posterior spinal fusion surgery may decrease intraoperative and postoperative bleeding and blood transfusion requirement.\(^4^1\) Javaherforoosh et al\(^4^2\) observed that 1 g of fibrinogen administered at time of incision to patients undergoing lumbar spine surgery also significantly decreased the need for blood products transfusion. Carling et al\(^4^3\) suggest that measuring the preoperative fibrinogen plasma concentration can identify spinal fusion patients with an increased risk of excessive perioperative bleeding. The limited literature on fibrinogen in spine surgery suggests that 1 g of fibrinogen administered 5 minutes after induction provides a hemostatic benefit and reduces postoperative bleeding. There is nonetheless no consensus on the timing of the administration and the correlation with the plasma fibrinogen levels. Studies in other surgical disciplines have demonstrated similar hemostatic benefits and safety of fibrinogen when administered preoperatively or intraoperatively at doses between 2 and 8 g. It remains unknown whether these findings can be translated to the field of spine surgery.

**CONCLUSIONS**

Fibrinogen plays a crucial role in the management of acute hemorrhage and remains an area of recent interest. A low level of fibrinogen leads to various complications such as low clot strength and
coagulopathies. Fibrinogen administration has been shown to be safer than allogenic blood product administration, and multiple studies in different disciplines have described hemostatic benefits and decreased intraoperative and postoperative blood loss. In addition, the ability to administer it almost immediately makes it an extremely useful therapy to have at your disposal.

The field of orthopedic surgery, more specifically spine surgery, is an area with a high risk of important hemorrhage that requires a great deal more research in regards to fibrinogen therapy. Pournajafian et al. has shown promising hemostatic benefits of intraoperative fibrinogen administration. Multiple authors have made similar observations across different surgical fields. Administration of 1 g of fibrinogen has been demonstrated to be safe and effective by Pournajafian et al. but some authors describe similar findings for doses up to 8 g. Further trials are required to understand the utility of fibrinogen concentrate as a first-line therapy in spine surgery and also to understand the importance of target fibrinogen levels and subsequent dosing and administration to allow recommendations to be made in this field.

REFERENCES

1. Francis JL. Hemostasis and thrombosis: basic principles and clinical practice. Blood Coagulation Fibrinol. 1994;5(5):855.
2. Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg. 1995;81(2):360–365.
3. Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion. 2014;54(5):1389–1405; quiz 1388.
4. Steinmetz J, Sørensen AM, Henriksen HH, et al. Pilot Randomized trial of Fibrinogen in Trauma Haemorrhage (PRooF-iTH): study protocol for a randomized controlled trial. Trials. 2016;17(1):327–327.
5. Rahe-Meyer N, Solomon C, Winterhalter M, et al. Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgery. J Thorac Cardiovasc Surg. 2009;138(3):694–702.
6. Karlsson M, Ternström L, Hyllner M, et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. Thromb Haemost. 2009;102(7):1137–1144.
7. Beyerle A, Nolte MW, Solomon C, Herzog E, Dickneite G. Analysis of the safety and pharmacodynamics of human fibrinogen concentrate in animals. Toxicol Appl Pharmacol. 2014;280(1):70–77.
8. Kreuz W, Meili E, Peter-Salonen K, et al. Pharmacokinetic properties of a pasteurised fibrinogen concentrate. Transfus Apher Sci. 2005;32(3):239–246.
9. Ariëns RAS. Novel mechanisms that regulate clot structure/function. Thromb Res. 2016;141:S25–S27.
10. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3(8):1894–1904.
11. Martini WZ, Chinkes DL, Pusateri AE, et al. Acute changes in fibrinogen metabolism and coagulation after hemorrhage in pigs. Am J Physiol Endocrinol Metab. 2005;289(5):E930–E934.
12. Darlington DN, Delgado AV, Kheirabadi BS, et al. Effect of hemodilution on coagulation and recombinant factor VIIa efficacy in human blood in vitro. J Trauma. 2011;71(5):1152–1163.
13. Franchini M, Lippi G. Fibrinogen replacement therapy: a critical review of the literature. Blood Transfus. 2012;10(1):23–27.
14. De Lorenzo C, Calatizis A, Welsch U, Heindl B. Fibrinogen concentrate reverses dilutional coagulopathy induced in vitro by saline but not by hydroxyethyl starch 6%. Anesth Analg. 2006;102(4):1194–1200.
15. Lang T, Johanning K, Metzler H, et al. The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. Anesth Analg. 2009;108(3):751–758.
16. Peyvandi F. Epidemiology and treatment of congenital fibrinogen deficiency. Thromb Res. 2012;130:S7–S11.
17. Bolliger D, Szal M, Molinaro RJ, Rahe-Meyer N, Levy JH, Tanaka KA. Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. Br J Anaesth. 2009;102(6):793–799.
18. Drenos F, Miller GJ, Humphries SE. Increase of plasma fibrinogen levels and variability with age in a sample of middle aged healthy men. Ann Hum Genet. 2007;71(1):43–53.
19. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica. 2007;92(6):846–849.
20. Schöchl H, Posch A, Hanke A, Voelckel W, Solomon C. High-dose fibrinogen concentrate for haemostatic therapy of a major trauma patient with recent clopidogrel and aspirin intake. Scand J Clin Lab Invest. 2010;70(6):453–457.
21. Willner D, Spennati V, Stohl S, Tosti G, Aloio S, Bilotta F. Spine surgery and blood loss. Anesth Analg. 2016;123(5):1307–1315.
22. Haas T, Spielmann N, Restin T, et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. Br J Anaesth. 2015;115(2):234–243.
23. Wikkelso AJ, Edwards HM, Afshari A, et al. Preemptive treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial. Br J Anaesth. 2015;114(4):623–633.
24. Bell SF, Raymond R, Collins PW, Collis RE. The use of fibrinogen concentrate to correct hypofibrinogenaemia rapidly during obstetric haemorrhage. Int J Obstet Anesth. 2010;19(2):218–223.
25. Shams Hakimi C, Singh S, Hesse C, Jeppsson A. Effects of fibrinogen and platelet transfusion on coagulation and platelet function in bleeding cardiac surgery patients. Acta Anaesthesiol Scand. 2019;63(4):475–482.
26. Lupi I-M, Rebaine Z, Lhotel L, et al. A low-dose human fibrinogen is not effective in decreasing postoperative bleeding
and transfusion requirements during cardiac surgery in case of concomitant clinical bleeding and low FIBTEM values: a retrospective matched study. Ann Card Anaesth. 2018;21(3):262–269.

27. Erdoes G, Koster A, Meesters MI, et al. The role of fibrinogen and fibrinogen concentrate in cardiac surgery: an international consensus statement from the Haemostasis and Transfusion Scientific Subcommittee of the European Association of Cardiothoracic Anaesthesiology. Anaesthesia. 2019;74(12):1589–1600. doi:10.1111/anae.14842

28. Li JY, Gong J, Zhu F, et al. Fibrinogen concentrate in cardiovascular surgery: a meta-analysis of randomized controlled trials. Anesth Analg. 2018;127(3):612–621.

29. Jahangirifard A, Ahmadi ZH, Naghashzadeh F, et al. Prophylactic fibrinogen decreases postoperative bleeding but not acute kidney injury in patients undergoing heart transplantation. Clin Appl Thromb Hemost. 2018;24(6):998–1004. doi:10.1177/1076029617731625

30. Bilecen S, De Groot JAH, Kalkman CJ, et al. Effect of fibrinogen concentrate on intraoperative blood loss among patients with intraoperative bleeding during high-risk cardiac surgery: A randomized clinical trial. JAMA - J Am Med Assoc. 2017;317(7):738–747. doi:10.1001/jama.2016.21037

31. Kikura M, Tobetto Y, Uehara H, et al. [Efficacy and indication of fibrinogen replacement therapy in thoracic aortic surgery a retrospective cohort study]. Masui. 2017;66(4):376–382.

32. Ranucci M, Baryshnikova E, Crapelli GB, et al. Surgical Clinical Outcome REsearch (SCORE) Group. Randomized, double-blind, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. J Am Heart Assoc. 2015;4(6):e002066. doi:10.1161/JAHA.115.002066

33. Yamamoto K, Usui A, Takamatsu J. Fibrinogen concentrate administration attributes to significant reductions of blood loss and transfusion requirements in thoracic aneurysm repair. J Cardiothorac Surg. 2014;9:90.

34. Rahe-Meyer N, Solomon C, Hanke A, et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery. Anesthesiology. 2013;118(1):40–50.

35. Bilecen S, Peelen LM, Kalkman CJ, Spanjersberg AJ, Moons KGM, Nierich AP. Fibrinogen concentrate therapy in complex cardiac surgery. J Cardiothorac Vasc Anesth. 2013;27(1):12–17. doi:10.1053/j.jvca.2012.06.006

36. Sadeghi M, Atefyekta R, Azimaraghi O, et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery. Braz J Anesthesiol. 2014;64(4):253–257. doi:10.1016/j.bjane.2013.10.010

37. Weiss G, Lison S, Glaser M, et al. Observational study of fibrinogen concentrate in massive hemorrhage: evaluation of a multicenter register. Blood Coagul Fibrinolysis. 2011;22(8):727–734. doi:10.1097/MBC.0b013e32834b343

38. Innerhofer P, Westermann I, Tauber H, et al. The exclusive use of coagulation factor concentrates enables reversal of coagulopathy and decreases transfusion rates in patients with major blunt trauma. Injury. 2013;44(2):209–216.

39. Najafi A, Moharrari RS, Orandi AA, et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: a randomized clinical trial study. Acta Medica Iranica. 2014;52(11):804–810.

40. Haas T, Fries D, Velik-Salchner C, Oswald E, Innerhofer P. Fibrinogen in craniosynostosis surgery. Anesth Analg. 2008;106(3):725–731. doi:10.1213/ane.0b013e318163fb26

41. Pourajafarian A, Ghodraty M, Mohseni M, Ghamari AA, Sadeghi F. Reduction of intraoperative bleeding with fibrinogen administration in posterior spinal fusion surgery. J Isfahan Med School. 2015;33(374):1370–1379.

42. Javaherforoosh Zadeh F, Jamatmakan F, Shafaei Tonekaboni M, Soltanazadeh M. The effect of fibrinogen on blood loss after lumbar surgery: a double-blind randomized clinical trial. Anesth Pain Med. 2019;9(3):e91199.

43. Carling MS, Zarhoud J, Jeppsson A, Eriksson BI, Brisby H. Preoperative plasma fibrinogen concentration, factor XIII activity, perioperative bleeding, and transfusions in elective orthopaedic surgery: a prospective observational study. Thromb Res. 2016;139:142–147.

44. Soleimani M, Masoumi N, Nooraei N, Lashay A, Safarinejad MR. The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double-blind placebo-controlled and randomized study. J Thromb Haemost. 2017;15(2):255–262. doi:10.1111/jth.13575

45. Fenger-Eriksen C, Jensen TM, Kristensen BS, et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. J Thromb Haemost. 2009;7(5):795–802.

46. Lavoie J. Blood transfusion risks and alternative strategies in pediatric patients. Pediatr Anesth. 2010;21(1):14–24.

47. Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding. Eur J Anaesthesiol. 2013;30(6):270–382.

48. Ziegler B, Schimke C, Marchet P, Stögermüller B, Schöchl H, Solomon C. Severe pediatric blunt trauma—successful ROTEM-guided hemostatic therapy with fibrinogen concentrate and no administration of fresh frozen plasma or platelets. Clin Appl Thromb Hemost. 2012;19(4):453–459.

49. Galas F, Hajjar L, Sorenson B, et al. Randomized comparison of fibrinogen concentrate versus cryoprecipitate for bleeding control in pediatric cardiac surgery (FICCS study). Crit Care. 2012;16(S1):P438.

50. Giordano P, Grassi M, Saracco P, et al. Human fibrinogen concentrate and fresh frozen plasma in the management of severe acquired hypofibrinogenemia in children with acute lymphoblastic leukemia: results of a retrospective survey. J Pediatr Hematol Oncol. 2019;41(4):275–279.

51. Theodoulou A, Berryman J, Nathwani A, Scully M. Comparison of cryoprecipitate with fibrinogen concentrate for acquired hypofibrinogenemia. Transfus Apher Sci. 2012;46(2):159–162.

52. Aawar N, Alikhan R, Bruynseels D, et al. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: study protocol for a randomised controlled trial. Trials. 2015;16:169.

53. Ducloy-Bouthors A-S, Mignon A, Huissoud C, Grouin J-M, Mercer JF. Fibrinogen concentrate as a treatment for postpartum haemorrhage-induced coagulopathy: a study protocol for a randomised multicentre controlled trial. The fibrinogen in haemorrhage of DELivery (FIDEL) trial. Anaesth Crit Care Pain Med. 2016;35(4):293–298.

54. Murad MH, Stubbs JR, Gandhi MJ, et al. The effect of plasma transfusion on morbidity and mortality: a systematic review and meta-analysis. Transfusion. 2010;50(6):1370–1383.

55. Murphy GJ, Reeves BC, Rogers CA, Rizvi SIA, Culliford L, Angelini GD. Increased mortality, postoperative
morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation. 2007;116(22):2544–2552.
56. Solomon C, Hagl C, Rahe-Meyer N. Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. Br J Anaesth. 2013;110(6):947–956.
57. Solomon C, Pichlmair U, Schoechl H, et al. Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth. 2010;104(5):555–562.
58. Moore FA, Moser KS, Read RA, Pons P. Epidemiology of trauma deaths. J Trauma. 1993;35(1):170.
59. Kauvar DS, Lefering R, Wade CE. Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. J Trauma. 2006;60(suppl):S3–S11.
60. Mittermayr M, Streif W, Haas T, et al. Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen administration. Anesth Analg. 2007;105(4):905–917.
61. Martini WZ. Fibrinogen metabolic responses to trauma. Scand J Trauma Resusc Emerg Med. 2009;17:2.
62. Caballo C, Galan AM, Diaz-Ricart M, et al. Reversion of the experimental hemodilutional coagulopathy induced by crystalloids and colloids using different coagulation factor concentrates. Blood. 2011;118(21):4349.
63. Schöchl H, Nienaber U, Maegle M, et al. Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care. 2011;15(2):R83.
64. Schlimp CJ, Ponschab M, Voelckel W, Treichl B, Maegle M, Schöchl H. Fibrinogen levels in trauma patients during the first seven days after fibrinogen concentrate therapy: a retrospective study. Scand J Trauma Resusc Emerg Med. 2016;24:29.
65. Nascimento B, Callum J, Tien H, et al. Fibrinogen in the initial resuscitation of severe trauma (FiIRST): a randomized feasibility trial. Br J Anaesth. 2016;117(6):775–782.
66. Winer J, Campbell D, Hurn C, et al. Fibrinogen in traumatic haemorrhage: a narrative review. Injury. 2017;48(2):230–242.
67. Jeong CW, Park YH, Ku JH, Kwak C, Kim HH. Minimally invasive management of postoperative bleeding after radical prostatectomy: transarterial embolization. J Endourol. 2010;24(9):1529–1533.
68. Thompson IM, Kappa SF, Morgan TM, et al. Blood loss associated with radical cystectomy: a prospective, randomized study comparing Impact LigaSure vs. stapling device. Urol Oncol. 2014;32(1):45.e11–45.e15.

Disclosures and COI: The authors received no funding for this study and report no conflicts of interest.

Corresponding Author: Bardia Barimani, MBBS, McGill University Health Centre, 1650 Cedar Ave, Montreal, Quebec, Canada H3G 1A4. Phone: (514) 686-5655; Email: bardia.barimani@mail.mcgill.ca.

Published 1 June 2021
This manuscript is generously published free of charge by ISASS, the International Society for the Advancement of Spine Surgery. Copyright © 2021 ISASS. To see more or order reprints or permissions, see http://ijssurgery.com.